Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP-SCIG 20% in primary immunodeficiency
NCT07346859Phase 3Recruiting
- Sponsor
- Biopharma Plasma
- Start
- Dec 2025
- Primary completion
- Apr 2028
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of subcuvia in primary immunodeficiency disease (PID), sponsored by Biopharma Plasma. Primary endpoints: Trough Plasma Concentration of Total IgG at Steady State at 12 months and Number of Serious Bacterial Infections per Subject per Year at 12 months. Started Dec 2025; status: recruiting.
02
Drugs
subcuvia
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT07346859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07346859.